Interv Akut Kardiol. 2007;6(5):178-180

Role of selective factor Xa inhibition in antithrombotic treatment

Ota Hlinomaz
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Factor Xa has an important role in the coagulation cascade. Selective factor-Xa inhibitors inhibit thrombin generation and thrombus formation. Rivaroxaban, otamixaban and apixaban are direct, selective factor Xa inhibitors. Fondaparinux and idraparinux selectively bind antithrombin and cause indirect inhibition of factor Xa. Fondaparinux was recently established as a leading antithrombotic drug in the treatment of acute coronary syndromes without ST segment elevation.

Keywords: factor Xa inhibitors, fondaparinux, acute coronary syndrome

Published: January 16, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlinomaz O. Role of selective factor Xa inhibition in antithrombotic treatment. Interv Akut Kardiol. 2007;6(5):178-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Friedewald VE, Bates ER, Granger CB, Yusuf S, Roberts WC. The Editor' s Roundtable: arterial thrombosis and acute coronary syndromes. Am J Cardiol. 2007; 100: 974-80. Go to original source... Go to PubMed...
    2. Studenčan M. Akutní koronární syndrom. Sport Media Group. Košice. 2007: 139-150.
    3. Hirsh J, O' Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560. Go to original source... Go to PubMed...
    4. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007; 5 Suppl1: 60-64. Go to original source... Go to PubMed...
    5. Ferguson JJ, Califf RM, Antman EM et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89-96. Go to original source... Go to PubMed...
    6. Cohen M, Bhatt DL, Alexander JH et al. on behalf of the SEPIA-PCI Trial Investigators. Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention. The SEPIA-PCI Trial Circulation 2007; 115: 2642-2651. Go to original source... Go to PubMed...
    7. Agnelli G, Gallus A, Goldhaber SZ et al. On behalf of the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. Circulation 2007; 116: 180-187. Go to original source... Go to PubMed...
    8. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007; 39 (5): 371-391. Go to original source... Go to PubMed...
    9. Eikelboom JW, Weitz JI. A replacement for warfarin. The search continues. Circulation 2007; 116: 131-133. Go to original source... Go to PubMed...
    10. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006: 6; 354: 1464-1476. Go to original source... Go to PubMed...
    11. Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-1751. Go to original source... Go to PubMed...
    12. Bassand JP, Richard-Lordereau I, Cadroy Y. Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007; 5: 1013-1026. Go to original source... Go to PubMed...
    13. Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S; OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007; 147: 304-310. Go to original source... Go to PubMed...
    14. Yusuf S, Mehta SR, Chrolavicius S; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519-1530. Go to original source... Go to PubMed...
    15. Califf RM. Fondaparinux in ST-segment elevation myocardial infarction. JAMA 2006; 295: 1579-1580. Go to original source... Go to PubMed...
    16. Bassand JP, Hamm CW, Ardissino D et al. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28: 1598-1660. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.